Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Triamcinolone Acetonide Injectable Suspension, Triesence
Triamcinolone Acetonide Injectable · 2 trials · 2 indications
A video image of the posterior segment structures of the eye was taken before instillation of the test product and after. An independent masked reader evaluated the images and graded the degree of visualization on a 5-point scale ranging from 1 to 4 and anchored at the ends by "Not Visible (0)" and "Clearly Delineated (4)." The mean difference was calculated, and a higher number indicated increased visibility.
Intraocular pressure (IOP) was measured by applanation tonometry in millimeters of mercury (mmHg). Surgical success was determined if IOP was \<21mmHg and 20% less than baseline IOP. Failure was defined as inability to meet criteria for success or IOP was less than 5mmHg.
| Arm | Type | Description |
|---|---|---|
| Triamcinolone | EXPERIMENTAL | Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal. |
| Treatment 1(Triesence) | EXPERIMENTAL | glaucoma surgery with 0.2cc Triesence adjunct. |
| Treatment 2 (balanced salt solution BSS) | ACTIVE_COMPARATOR | glaucoma surgery with balanced salt solution, the standard technique. |
| Name | Type | Description |
|---|---|---|
| Triamcinolone Acetonide Injectable Suspension | DRUG | Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal. |
| Triesence | DRUG | At end of standard glaucoma surgery and the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure, 0.2cc of Triesence will be delivered into the anterior chamber through the previously created paracentesis wound. |
| balanced salt solution BSS | DRUG | At end of standard glaucoma surgery, the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure. |
Inclusion Criteria: * Patients planning to undergo pars plana vitrectomy with good vision in the non-surgery eye. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Patients under 18. * Patients with previous vitrectomy, elevated intraocular pressure (IOP) and/or history...
Triamcinolone acetonide injectable is a small molecule formulation developed by Alcon Inc. (ticker ALC) for use during vitrectomy, a surgical procedure on the eye. It is an investigational product in Phase 3 clinical development in the ophthalmology therapeutic area.
Triamcinolone acetonide injectable is being studied for use during vitrectomy, where it is evaluated as a vitreous delineating agent to help visualize the vitreous gel during the surgical procedure. Its development is focused on this ophthalmology indication under Alcon Inc.
Triamcinolone acetonide injectable targets NR3C1, the glucocorticoid receptor, and acts as an agonist at this receptor. NR3C1 agonism is the mechanism associated with this small molecule in its development for use during vitrectomy.
Triamcinolone acetonide injectable is developed by Alcon Inc., which trades under the ticker ALC. Alcon is the sponsor associated with the clinical development of this ophthalmology asset.
Triamcinolone acetonide injectable is in Phase 3 clinical development. It is an investigational product and is not described as approved; its development program in vitrectomy includes one completed Phase 3 trial.
Triamcinolone acetonide injectable has been studied in one completed Phase 3 trial, NCT00532415, titled Safety and Efficacy of Vitreous Delineating Agent During Vitrectomy. That trial enrolled 60 participants aged 18 years and older and was an uncontrolled study.
Yes, triamcinolone acetonide injectable is also known as triamcinolone acetonide injectable suspension. Both names refer to the same Alcon Inc. product candidate being developed for use during vitrectomy.